CCA
VIVO

Conestoga Capital Advisors’s Meridian Bioscience Inc VIVO Stock Holding History

Conestoga Capital Advisors’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-737,319
Closed -$15.2M – 126
2014
Q2 		$15.2M Buy
737,319
+6,722
+0.9% +$138K 1.02% 43
2014
Q1 		$15.9M Sell
730,597
-260,915
-26% -$5.98M 1.01% 41
2013
Q4 		$26.3M Buy
991,512
+105,760
+12% +$2.6M 1.77% 33
2013
Q3 		$20.9M Buy
885,752
+73,450
+9% +$1.72M 1.79% 30
2013
Q2 		$17.5M Buy
+812,302
New +$17.5M 1.8% 28

Other funds holding VIVO

BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CPCM
Clifton Park Capital Management Wilmington, Delaware $881M AUM 5.59% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
ACM
Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return

Conestoga Capital Advisors's VIVO Position: Q3 2014 in Review

Conestoga Capital Advisors sold out of Meridian Bioscience Inc (VIVO) in Q3 2014, closing a stake of 737,319 shares — an estimated $15.2M sold.

Conestoga Capital Advisors first reported a position in VIVO in Q2 2013 and held it in 5 quarters. The position peaked at $26.3M in Q4 2013. 161 funds tracked by Wall St. Rank hold VIVO as of Q3 2014.

  • Conestoga Capital Advisors reported no remaining Meridian Bioscience Inc position as of Q3 2014 after selling out during the quarter.
  • Conestoga Capital Advisors sold 737,319 Meridian Bioscience Inc shares in Q3 2014, an estimated $15.2M.
  • Conestoga Capital Advisors first reported a position in Meridian Bioscience Inc in Q2 2013 and held it in 5 quarters.
  • Conestoga Capital Advisors's Meridian Bioscience Inc position peaked at $26.3M in Q4 2013.
  • 161 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q3 2014.

Based on Conestoga Capital Advisors's 13F filing for Q3 2014, filed 7 Nov 2014.